Lv5
850 积分 2023-12-04 加入
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
10天前
已完结
The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
17天前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
23天前
已完结
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
1个月前
已完结
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials
1个月前
已关闭
G4-PROTAC: targeted degradation of a G-quadruplex binding protein
1个月前
已完结
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates
1个月前
已完结
The graphical representation of ADME-related molecule properties for medicinal chemists
1个月前
已完结
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
1个月前
已完结
Structure-based design of non-hypertrophic apelin receptor modulator
2个月前
已完结
皖公网安备34019202002308
